CA2365240C - Regulation of phospholipase d activity - Google Patents

Regulation of phospholipase d activity Download PDF

Info

Publication number
CA2365240C
CA2365240C CA002365240A CA2365240A CA2365240C CA 2365240 C CA2365240 C CA 2365240C CA 002365240 A CA002365240 A CA 002365240A CA 2365240 A CA2365240 A CA 2365240A CA 2365240 C CA2365240 C CA 2365240C
Authority
CA
Canada
Prior art keywords
inclusive
carbon atoms
branched
straight chain
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002365240A
Other languages
English (en)
French (fr)
Other versions
CA2365240A1 (en
Inventor
Charles N. Serhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Priority to CA2645558A priority Critical patent/CA2645558C/en
Publication of CA2365240A1 publication Critical patent/CA2365240A1/en
Application granted granted Critical
Publication of CA2365240C publication Critical patent/CA2365240C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002365240A 1999-03-18 2000-03-14 Regulation of phospholipase d activity Expired - Fee Related CA2365240C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2645558A CA2645558C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12519499P 1999-03-18 1999-03-18
US60/125,194 1999-03-18
PCT/US2000/006669 WO2000054761A2 (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2645558A Division CA2645558C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Publications (2)

Publication Number Publication Date
CA2365240A1 CA2365240A1 (en) 2000-09-21
CA2365240C true CA2365240C (en) 2009-01-20

Family

ID=22418604

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002365240A Expired - Fee Related CA2365240C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity
CA2645558A Expired - Fee Related CA2645558C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2645558A Expired - Fee Related CA2645558C (en) 1999-03-18 2000-03-14 Regulation of phospholipase d activity

Country Status (10)

Country Link
US (5) US6353026B1 (enExample)
EP (2) EP2236140A1 (enExample)
JP (1) JP4392473B2 (enExample)
AT (1) ATE466582T1 (enExample)
AU (1) AU780114B2 (enExample)
CA (2) CA2365240C (enExample)
DE (1) DE60044335D1 (enExample)
ES (1) ES2344138T3 (enExample)
HK (1) HK1043306B (enExample)
WO (1) WO2000054761A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) * 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
WO2000048092A2 (en) * 1999-02-12 2000-08-17 Mount Sinai Hospital System for electronically managing, finding, and/or displaying biomolecular interactions
US6745204B1 (en) * 1999-02-12 2004-06-01 Mount Sinai Hospital System for electronically managing, finding, and/or displaying biomolecular interactions
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
WO2000054761A2 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Regulation of phospholipase d activity
HK1043357B (en) 1999-03-18 2005-12-09 The Brigham And Women's Hospital, Inc. LIPOXIN compound and its use
EP1586550A1 (en) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP1441715B1 (en) * 2001-11-06 2013-02-27 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004014835A2 (en) * 2002-08-12 2004-02-19 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
BRPI0614693A2 (pt) 2005-07-29 2011-04-12 Monsanto Technology Llc desenvolvimento de germoplasma usando segregados de cruzamentos transgênicos
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
EP2049099A1 (en) * 2006-07-19 2009-04-22 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
EP2131833A2 (en) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Use of resolvins for inhibition of bone loss
PE20120395A1 (es) 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
EP2207543A2 (en) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
US20090118243A1 (en) * 2007-10-12 2009-05-07 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
KR101306199B1 (ko) 2012-01-31 2013-09-09 부산대학교 산학협력단 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물
WO2014084868A1 (en) 2012-12-01 2014-06-05 Halliburton Energy Services, Inc. Protection of electronic devices used with perforating guns

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
EP1657233A1 (en) * 1993-06-15 2006-05-17 The Brigham & Women's Hospital, Inc. Lipoxin compounds
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
AU7215294A (en) 1993-06-29 1995-01-24 Brigham And Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
HK1043357B (en) * 1999-03-18 2005-12-09 The Brigham And Women's Hospital, Inc. LIPOXIN compound and its use
WO2000054761A2 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Regulation of phospholipase d activity
CA2615917C (en) 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response

Also Published As

Publication number Publication date
EP1162976A2 (en) 2001-12-19
DE60044335D1 (de) 2010-06-17
ES2344138T3 (es) 2010-08-19
US20050187294A1 (en) 2005-08-25
US20080064751A1 (en) 2008-03-13
US6353026B1 (en) 2002-03-05
AU780114B2 (en) 2005-03-03
HK1043306B (en) 2010-09-17
JP4392473B2 (ja) 2010-01-06
AU3745100A (en) 2000-10-04
WO2000054761A2 (en) 2000-09-21
CA2645558A1 (en) 2000-09-21
WO2000054761A9 (en) 2001-10-25
ATE466582T1 (de) 2010-05-15
WO2000054761A3 (en) 2001-03-29
US20020120013A1 (en) 2002-08-29
HK1043306A1 (en) 2002-09-13
EP2236140A1 (en) 2010-10-06
EP1162976B1 (en) 2010-05-05
CA2645558C (en) 2012-05-15
US6864288B2 (en) 2005-03-08
US20020107289A1 (en) 2002-08-08
CA2365240A1 (en) 2000-09-21
JP2002539156A (ja) 2002-11-19
US6927238B2 (en) 2005-08-09

Similar Documents

Publication Publication Date Title
CA2365240C (en) Regulation of phospholipase d activity
Levy et al. Polyisoprenyl phosphate (PIPP) signaling regulates phospholipase D activity: a ‘stop’signaling switch for aspirin‐triggered lipoxin A4
AU2009201390C1 (en) A novel approach to antimicrobial host defense against gram-negative infections
CA2265708C (en) Lipoxin compounds and their use in treating cell proliferative disorders
US20030166716A1 (en) Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2008058274A2 (en) Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
Dew et al. Effects of pharmacological retinoids on several vitamin A-metabolizing enzymes
AU2009208104B2 (en) Regulation of phospholipase D activity
AU2005202416B2 (en) Regulation of phospholipase D activity
CA2768688A1 (en) Regulation of phospholipase d activity
AU2012203490A1 (en) Regulation of phospholipase D activity
US5567729A (en) Farnesyl compounds as farnesyl protein transferase inhibitors to treat ras induced tumor growth
Spokas et al. Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids
Clish et al. Local and systemic delivery of an aspirin-triggered lipoxin stable analog inhibits neutrophil trafficking
Robinson et al. Inhibition of phorbol ester-stimulated arachidonic acid release by alkylglycerols
NAGATA et al. Effects of simvastatin (MK-733) on branched pathway of mevalonate
EP1911448A2 (en) Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
HK1161556A (en) Use of lipoxin analogs to promote cell defense against gram-negative infections

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150316